Hikal invests Rs. 500 crore into fine chemicals plant at Panoli

Signs MoU with the Govt. of Gujarat at Vibrant Gujarat Summit

Hikal receives Brazilian GMP certification and USFDA EIR for Bangalore and Panoli facilities

Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr

US FDA approval is in line with de-risking strategy for additional API site to service our global customer base

Hikal posts FY23 PAT at Rs. 36 Cr

Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22

Hikal announces USFDA audit with zero observations

This latest audit re-emphasizes Hikal's commitment towards maintaining the best in class quality, compliance and regulatory standards across our manufacturing sites

Hikal shows 17% degrowth in Q1 FY23

Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore

Green chemistry approaches to synthesis could make a big difference to pharma product outputs

Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies

Green ChemisTree Foundation announces virtual conference on Innovations in Green & Sustainable Chemistry for Pharma Industry

Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness